Results 71 to 80 of about 35,405 (287)

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Primary liver cancer organoids and their application to research and therapy

Journal of the National Cancer Center
Primary liver cancer is a leading cause of death worldwide. To create advanced treatments for primary liver cancer, studies have utilized models such as 2D cell culture and in vivo animal models.
Xiaobin Zhu, Rajiv Trehan, Changqing Xie
doaj   +1 more source

SARS-CoV-2 infection of human pluripotent stem cell-derived liver organoids reveals potential mechanisms of liver pathology [PDF]

, 2022
Alexsia Richards, Max Friesen, Andrew Khalil, M. Inmaculada Barrasa, Lee Gehrke, Rudolf Jaenisch   +5 more
openalex   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. [PDF]

, 2015
The study of biliary disease has been constrained by a lack of primary human cholangiocytes. Here we present an efficient, serum-free protocol for directed differentiation of human induced pluripotent stem cells into cholangiocyte-like cells (CLCs). CLCs
A Antoniou, A Caroli, A Gigliozzi, A Haack, A Shenoy, Alastair Baker, Alessandro Bertero, Arthur Kaser, AY Gong, C Colombo, CL Ward, D Cízková, D Zhao, DA Robinton, Elisabeth Schrumpf, Espen Melum, F Clotman, F Geisler, F Temmerman, F Van Goor, Filipa A C Soares, Fotios Sampaziotis, GK Smyth, Graeme J Alexander, J Andrew Bradley, JC Davies, JP Clancy, K Si-Tayeb, K Staufer, K Takahashi, KF Murray, KN Lazaridis, Kourosh Saeb-Parsy, Ludovic Vallier, M Yanai, Miguel Cardoso de Brito, MJ Pollheimer, N Chandok, N Dianat, N Kanno, N Minagawa, N Tanimizu, Nicholas R F Hannan, NR Hannan, NR Hannan, P Du, P Raynaud, PD Turnpenny, Pedro Madrigal, RA Marinelli, SJ Bray, SM Rowe, SS Saravanamuthu, ST Rashid, Susan Davies, TJ Caperna, Tom H Karlsen, TV Masyuk, William T H Gelson, X Xia, Y Benjamini, Y Zong   +61 more
core   +4 more sources

Preclinical Models: Boosting Synergies for Improved Translation [PDF]

, 2020
The field of preclinical models is a very vast arena, in which finding connections among groups acting in apparently very distant research areas can sometimes prove challenging [...
Attanasio C., Sangiovanni M.
core   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease [PDF]

, 2023
Yinhan Wang, Haifeng Xu
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

3D Co-Culture of Hepatocyte, a Hepatic Stellate Cell Line, and Stem Cells for Developing a Bioartificial Liver Prototype

International Journal of Technology, 2020
A liver organoid is an in vitro reconstruction of the liver that mimics the in vivo liver microstructure and performs liver functions. Liver organoids can be used for drug testing, as a model of liver disease pathogenesis, and as a bioartificial ...
Christine Verawaty Sibuea, Jeanne Pawitan, Radiana Antarianto, Cynthia O.M. Jasirwan, Imelda Rosalyn Sianipar, Evah Luviah, Retno Wahyu Nurhayati, Wildan Mubarok, Nuzli Fahdia Mazfufah   +8 more
doaj   +1 more source